Evidence map›Paper›PMID 41022865›Full record

ArticleNPJ vaccines2025

Synergistic effect of nucleoside modification and ionizable lipid composition on translation and immune responses to mRNA vaccines.

Hillary Danz, Allison Dauner, Shraddha Sharma, Mihaela Babiceanu, Nicholas Clark, Robert Jordan Ontiveros, Robert Amezquita, Alisa Zhilin-Roth, Eric Reyes, Catherine Khoo and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Hillary Danz *mRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Allison Dauner *mRNA Center of Excellence, Sanofi, Orlando, FL, USA.
Shraddha SharmamRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Mihaela BabiceanumRNA Center of Excellence, Sanofi, Orlando, FL, USA.
Nicholas ClarkmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Robert Jordan OntiverosmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Robert AmezquitamRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Alisa Zhilin-RothmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Eric ReyesmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Catherine KhoomRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Kara GilbertmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Janhavi NadkarnimRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Omkar ChaudharymRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Christina LeemRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Ana KumemRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Azadeh BahadoranmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Mona MotwanimRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Bin LumRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Wei ZongmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Andrew KettringmRNA Center of Excellence, Sanofi, Orlando, FL, USA.
Alex ShumatemRNA Center of Excellence, Sanofi, Orlando, FL, USA.
Shrirang KarvemRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Anusha DiasmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Monica WumRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Xiaobo GumRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Yanhua YanmRNA Center of Excellence, Sanofi, Waltham, MA, USA.
Daniel G AndersonDavid H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Brian SchanenmRNA Center of Excellence, Sanofi, Orlando, FL, USA.
Sudha ChivukulamRNA Center of Excellence, Sanofi, Waltham, MA, USA. sudha.chivukula@sanofi.com.ORCID http://orcid.org/0000-0002-1832-1465
Frank DeRosamRNA Center of Excellence, Sanofi, Waltham, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid nanoparticle (LNP) components can impact the safety and immunogenicity of mRNA vaccines. Here we examine the mechanisms contributing to the performance of mRNA-LNP vaccines by exploring the impact of nucleoside modifications and LNP components on translational efficiency, innate immune activation, and immunogenicity. Our data reveals several molecular and immunological parameters affected by nucleoside modification including a synergistic effect of the mRNA and ionizable lipid composition on the immune activation triggered by the mRNA-LNP formulation. Our results indicate changes in the LNP composition, independent from whether the mRNA is modified or unmodified, caused differential expression of genes associated with innate and antiviral immunity. We believe these findings offer valuable insights into mRNA vaccine function and offer strategies for enhancing vaccine efficacy and reducing the reactogenicity of next generation mRNA vaccines.

Identifiers

PMID41022865
PMCPMC12479783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.